Beata Fiuk
Adult Health · New York, NYNPI 1336574524
Payments from drug & device makers
Across 304 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Novo Nordisk$852
- Gilead$818
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$551
- Amgen$533
- plus $3K from 23 others
What the payments were for
- Food & beverage$9,060100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 72 | $2,423 |
| AbbVie | 53 | $1,255 |
| Novo Nordisk | 16 | $852 |
| Gilead | 14 | $818 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $551 |
| Amgen(2 entities) | 18 | $533 |
| Boehringer Ingelheim | 17 | $503 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $415 |
| GSK | 18 | $400 |
| Sanofi | 6 | $199 |
| Lilly USA, LLC | 7 | $162 |
| Bayer | 7 | $143 |
| Lundbeck LLC | 7 | $139 |
| Exact Sciences | 4 | $101 |
| Almatica Pharma LLC | 3 | $71 |
| Kowa Pharmaceuticals America, Inc. | 4 | $69 |
| Ardelyx, Inc. | 2 | $54 |
| Astellas Pharma US Inc | 2 | $53 |
| Novartis | 3 | $48 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Phadia US Inc. | 2 | $42 |
| Merck | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $24 |
| Pfizer | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,060 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 42 | $42,782 |
| ZenpepLipase/Protease/Amylase | 20 | $37,188 |
| EliquisApixaban | 20 | $22,445 |
| CreonLipase/Protease/Amylase | 11 | $20,969 |
| ProliaDenosumab | 11 | $18,231 |
| LinzessLinaclotide | 27 | $17,715 |
| JanuviaSitagliptin Phosphate | 14 | $16,444 |
| VraylarCariprazine Hcl | 11 | $15,191 |
| TradjentaLinagliptin | 25 | $12,606 |
| OzempicSemaglutide | 13 | $11,767 |
| FarxigaDapagliflozin Propanediol | 16 | $11,246 |
| JentaduetoLinagliptin/Metformin Hcl | 18 | $9,528 |
| NamzaricMemantine Hcl/Donepezil Hcl | 16 | $9,007 |
| CrestorRosuvastatin Calcium | 17 | $8,340 |
| EntrestoSacubitril/Valsartan | 11 | $7,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $503 | $64,91585 claims |
| AbbVieCreon, Linzess, Vraylar, Namzaric | $1,255 | $62,88265 claims |
| Aimmune Therapeutics, Inc.Zenpep | $18 | $37,18820 claims |
| PfizerEliquis | $24 | $22,44520 claims |
| AstraZenecaFarxiga, Crestor | $2,423 | $19,58633 claims |
| AmgenProlia | $533 | $18,23111 claims |
| MerckJanuvia | $31 | $16,44414 claims |
| Novo NordiskOzempic | $852 | $11,76713 claims |
| NovartisEntresto | $48 | $7,56911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in New York
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Alyson HartyNew York$65K
- Laura GraaflandNew York$51K
- Allysa SaggeseNew York$49K
- Juliet EscalonNew York$46K
- Teshmanie RampersaudNew York$23K
- Jenna WenzelNew York$22K
- Elizabeth SavageNew York$20K
- Libby LevineNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.